Quarterly report pursuant to Section 13 or 15(d)

Revenue from Contracts with Customers

v3.19.3
Revenue from Contracts with Customers
9 Months Ended
Sep. 30, 2019
Revenue from Contract with Customer [Abstract]  
Revenue from Contracts with Customers
Revenue from Contracts with Customers

The Company generates substantially all of its revenue from sales of prescription pharmaceutical products to its customers. The following table presents net revenues disaggregated by type (in thousands):

 
 
Three Months Ended
 
Nine Months Ended
 
 
September 30,
 
September 30,
 
 
2019
 
2018
 
2019
 
2018
Prescribed dietary supplements
 
$
2,318

 
$
2,097

 
$
5,909

 
$
5,767

Prescription drugs
 
3,195

 
1,978

 
9,465

 
7,279

License and other revenue
 
100

 

 
100

 

Sales force revenue
 

 

 

 
297

Total revenue
 
$
5,613

 
$
4,075

 
$
15,474

 
$
13,343



As is typical in the pharmaceutical industry, the Company sells its prescription pharmaceutical products (which include prescribed dietary supplements and prescription drugs) in the United States primarily through wholesale distributors and a specialty contracted pharmacy. Wholesale distributors account for substantially all of the Company’s net product revenues and trade receivables. In addition, the Company earns revenue from sales of its prescription pharmaceutical products directly to retail pharmacies.   For the three months ended September 30, 2019, the Company’s three largest customers accounted for approximately 32%, 31%, and 27% of the Company's total net product revenues from sale of prescription pharmaceutical products. For the nine months ended September 30, 2019, the Company's three largest customers accounted for approximately 35%, 31%, and 26% of the Company's total net product revenues from sale of prescription pharmaceutical products.